In short
Clinical trials are investigating Mbf-015 in people with Huntington's disease. This article explains what the study is testing, who took part, and which results were measured, such as safety, tolerability, and early signs of benefit. The available trial is a phase 2 study with a small group of patients.
Key points
- Mbf-015 is being studied in a phase 2 clinical trial in people with Huntington's disease. The trial was open label and done at one centre, with 10 participants enrolled. Researchers looked mainly at safety and tolerability over 28 days, and they also checked early signs of benefit. The study measured adverse events, vital signs, physical exams, lab tests, ECGs, and C-SSRS results. The trial status is completed, with follow-up through day 43.
Trial overview
This clinical trial studied Mbf-015 in people with Huntington's disease. The study was designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy over a 28-day treatment period.
The trial was completed and enrolled 10 participants.
Study design and phase
This was a phase 2 study, which means it was a mid-stage trial that looked more closely at how the treatment performed in patients. It was also open label, so the research team and the participants knew what treatment was being given.
The study was single centre, meaning it took place at one research site. The intervention was oral Mbf-015, given as 32 mg by mouth.
Who participated
The target population was people with Huntington's disease. The brief summary says the trial studied Mbf-015 in participants with Huntington's disease on top of standard of care, which means usual treatment was continued during the study.
Because only 10 people were enrolled, this was a small study meant to gather early clinical information rather than prove long-term benefit.
What was measured
The main endpoint was safety and tolerability from baseline to the end of follow-up on day 43. Safety means whether the treatment caused harmful problems, and tolerability means how well patients could handle the treatment.
Researchers counted and graded adverse events, which are unwanted medical problems that happen during a study. They also looked for clinically significant changes in vital signs, physical examination findings, laboratory measurements, ECGs, and the Columbia-Suicide Severity Rating Scale (C-SSRS).
The study also aimed to assess pharmacokinetics and pharmacodynamics. Pharmacokinetics describes how the body handles a treatment, while pharmacodynamics describes how the treatment affects the body.
Safety and follow-up tracking
Participants were followed for 28 days of treatment, with follow-up continuing to day 43. This follow-up period helped the researchers watch for later safety findings after the main treatment period ended.
The available trial data do not report detailed outcome results in the source, but they do show that the study was completed and focused on early clinical evaluation of Mbf-015 in Huntington's disease.